Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis.

Jonsson MK, Kantyka T, Falkowski K, Aliko A, Aga AB, Lillegraven S, Sexton J, Fevang BT, Mydel P, Haavardsholm EA.

Scand J Rheumatol. 2019 Sep 23:1-9. doi: 10.1080/03009742.2019.1641216. [Epub ahead of print]

PMID:
31544586
2.

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.

Holmøy T, Fevang B, Olsen DB, Spigset O, Bø L.

BMC Res Notes. 2019 Aug 12;12(1):497. doi: 10.1186/s13104-019-4507-6.

3.

Risk of Cancer in 767 Patients with Giant Cell Arteritis in Western Norway: A Retrospective Cohort with Matched Controls.

Brekke LK, Fevang BS, Diamantopoulos AP, Assmus J, Esperø E, Gram Gjesdal C.

J Rheumatol. 2019 Jul 15. pii: jrheum.190147. doi: 10.3899/jrheum.190147. [Epub ahead of print]

PMID:
31308209
4.

Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency.

Macpherson ME, Halvorsen B, Yndestad A, Ueland T, Mollnes TE, Berge RK, Rashidi A, Otterdal K, Gregersen I, Kong XY, Holven KB, Aukrust P, Fevang B, Jørgensen SF.

Sci Rep. 2019 Jul 1;9(1):9427. doi: 10.1038/s41598-019-45861-1.

5.

Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Brekke LK, Fevang BS, Diamantopoulos AP, Assmus J, Esperø E, Gjesdal CG.

Arthritis Res Ther. 2019 Jun 25;21(1):154. doi: 10.1186/s13075-019-1945-4.

6.

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK.

J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12.

7.

Selective IgA deficiency in humans is associated with reduced gut microbial diversity.

Jørgensen SF, Holm K, Macpherson ME, Storm-Larsen C, Kummen M, Fevang B, Aukrust P, Hov JR.

J Allergy Clin Immunol. 2019 May;143(5):1969-1971.e11. doi: 10.1016/j.jaci.2019.01.019. Epub 2019 Jan 29. No abstract available.

PMID:
30707969
8.

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B.

Sci Rep. 2019 Jan 17;9(1):167. doi: 10.1038/s41598-018-35367-7.

9.

Increased Incidence of Giant Cell Arteritis in Urban Areas?

Brekke LK, Fevang BT, Myklebust G.

J Rheumatol. 2019 Mar;46(3):327-328. doi: 10.3899/jrheum.180714. Epub 2019 Jan 15. No abstract available.

PMID:
30647168
10.

Soluble markers of neutrophil, T-cell and monocyte activation are associated with disease severity and parasitemia in falciparum malaria.

Otterdal K, Berg A, Michelsen AE, Patel S, Tellevik MG, Haanshuus CG, Fevang B, Aukrust P, Langeland N, Ueland T.

BMC Infect Dis. 2018 Dec 18;18(1):670. doi: 10.1186/s12879-018-3593-8.

11.

Tendering for HIV drugs is not clinically justified.

Trøseid M, Nordøy I, Fevang B, Aukrust P.

Tidsskr Nor Laegeforen. 2018 Nov 30;138(20). doi: 10.4045/tidsskr.18.0808. Print 2018 Dec 11. Norwegian. No abstract available.

12.

Malaria and Malnutrition: Kwashiorkor Associated with Low Levels of Parasitaemia.

Fevang P, Havemann K, Fevang B, Høstmark AT.

Malar Res Treat. 2018 Sep 27;2018:7153173. doi: 10.1155/2018/7153173. eCollection 2018.

13.

Correction to: Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Brekke LK, Diamantopoulos AP, Fevang BT, Aβmus J, Esperø E, Gjesdal CG.

Arthritis Res Ther. 2018 Dec 7;20(1):271. doi: 10.1186/s13075-018-1781-y.

14.

Autoimmunity and Inflammation in CVID: a Possible Crosstalk between Immune Activation, Gut Microbiota, and Epigenetic Modifications.

Jørgensen SF, Fevang B, Aukrust P.

J Clin Immunol. 2019 Jan;39(1):30-36. doi: 10.1007/s10875-018-0574-z. Epub 2018 Nov 21. Review.

PMID:
30465180
15.

Donor-derived strongyloidiasis after organ transplantation in Norway.

Nordheim E, Olafsson Storrø M, Natvik AK, Birkeland Kro G, Midtvedt K, Varberg Reisaeter A, Hagness M, Fevang B, Pettersen FO.

Transpl Infect Dis. 2019 Feb;21(1):e13008. doi: 10.1111/tid.13008. Epub 2018 Oct 28.

PMID:
30295406
16.

Incidence and Predictive Factors for Orthopedic Surgery in Patients with Psoriatic Arthritis.

Nystad TW, Husum YS, Furnes ON, Fevang BS.

J Rheumatol. 2018 Nov;45(11):1532-1540. doi: 10.3899/jrheum.180203. Epub 2018 Sep 1.

PMID:
30173150
17.

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases.

Ikdahl E, Wibetoe G, Rollefstad S, Salberg A, Bergsmark K, Kvien TK, Olsen IC, Soldal DM, Bakland G, Lexberg Å, Fevang BTS, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2019 Jan 1;274:311-318. doi: 10.1016/j.ijcard.2018.06.111. Epub 2018 Jul 2.

PMID:
30007486
18.

The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.

Jonsson MK, Hensvold AH, Hansson M, Aga AB, Sexton J, Mathsson-Alm L, Cornillet M, Serre G, Lillegraven S, Fevang BS, Catrina AI, Haavardsholm EA.

Arthritis Res Ther. 2018 Jul 13;20(1):146. doi: 10.1186/s13075-018-1635-7.

19.

Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas.

Fevang B, Fagerli UM, Sorte H, Aarset H, Hov H, Langmyr M, Keil TM, Bjørge E, Aukrust P, Stray-Pedersen A, Gedde-Dahl T.

Case Reports Immunol. 2018 May 14;2018:2053716. doi: 10.1155/2018/2053716. eCollection 2018.

20.

Predictors for orthopaedic surgery in patients with rheumatoid arthritis: results from a retrospective cohort study of 1010 patients diagnosed from 1972 to 2009 and followed up until 2015.

Nystad TW, Fenstad AM, Furnes O, Fevang BT.

Scand J Rheumatol. 2018 Jul;47(4):282-290. doi: 10.1080/03009742.2017.1397188. Epub 2018 Feb 15.

PMID:
29447542
21.

A Young, Immunocompetent Woman with Small Bowel and Hepatic Mucormycosis Successfully Treated with Aggressive Surgical Debridements and Antifungal Therapy.

Vikum D, Nordøy I, Torp Andersen C, Fevang B, Line PD, Kolrud FK, Aukrust P, Buanes T.

Case Rep Infect Dis. 2017;2017:4173246. doi: 10.1155/2017/4173246. Epub 2017 Dec 24.

22.

Open access - elefanten (eller isbjørnen) i rommet.

Fevang B.

Tidsskr Nor Laegeforen. 2018 Jan 22;138(2). doi: 10.4045/tidsskr.18.0019. Print 2018 Jan 23. Norwegian. No abstract available.

PMID:
29357620
Free Article
23.

Response to: 'Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau et al.

Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, van der Heijde D, Kvien TK, Fevang BS, Lillegraven S, Haavardsholm EA.

Ann Rheum Dis. 2018 Dec;77(12):e85. doi: 10.1136/annrheumdis-2017-212869. Epub 2018 Jan 10. No abstract available.

PMID:
29321158
24.

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Int J Cardiol. 2018 Feb 1;252:201-206. doi: 10.1016/j.ijcard.2017.10.038.

PMID:
29249429
25.

Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Brekke LK, Diamantopoulos AP, Fevang BT, Aβmus J, Esperø E, Gjesdal CG.

Arthritis Res Ther. 2017 Dec 15;19(1):278. doi: 10.1186/s13075-017-1479-6. Erratum in: Arthritis Res Ther. 2018 Dec 7;20(1):271.

26.

Open access - elefanten (eller isbjørnen) i rommet.

Fevang B.

Tidsskr Nor Laegeforen. 2017 Dec 12;137(23-24). doi: 10.4045/tidsskr.17.1010. Print 2017 Dec 12. Norwegian. No abstract available.

PMID:
29231632
Free Article
27.

TLR9 stimulation of B-cells induces transcription of p53 and prevents spontaneous and irradiation-induced cell death independent of DNA damage responses. Implications for Common variable immunodeficiency.

Holm KL, Syljuåsen RG, Hasvold G, Alsøe L, Nilsen H, Ivanauskiene K, Collas P, Shaposhnikov S, Collins A, Indrevær RL, Aukrust P, Fevang B, Blomhoff HK.

PLoS One. 2017 Oct 3;12(10):e0185708. doi: 10.1371/journal.pone.0185708. eCollection 2017.

28.

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.

Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, Brokstad KA, van der Heijde D, Kvien TK, Fevang BS, Lillegraven S, Haavardsholm EA.

Ann Rheum Dis. 2017 Dec;76(12):2031-2037. doi: 10.1136/annrheumdis-2017-211695. Epub 2017 Aug 16.

PMID:
28814431
29.

Cardiovascular disease risk profiles in inflammatory joint disease entities.

Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, Salberg A, Soldal DM, Bakland G, Lexberg Å, Fevang BT, Gulseth HC, Haugeberg G, Semb AG.

Arthritis Res Ther. 2017 Jul 3;19(1):153. doi: 10.1186/s13075-017-1358-1.

30.

Defective IL-4 signaling in T cells defines severe common variable immunodeficiency.

Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J.

J Autoimmun. 2017 Jul;81:110-119. doi: 10.1016/j.jaut.2017.04.004. Epub 2017 May 3.

PMID:
28476239
31.

Erratum: Common Variable Immunodeficiency patients with a phenotypic profile of immunosenescence present with thrombocytopenia.

Stuchlý J, Kanderová V, Vlková M, Heřmanová I, Slámová L, Pelák O, Taraldsrud E, Jílek D, Králíčková P, Fevang B, Trková M, Hrušák O, Froňková E, Šedivá A, Litzman J, Kalina T.

Sci Rep. 2017 Feb 27;7:42569. doi: 10.1038/srep42569. No abstract available.

32.

CVID and Celiac Disease.

Jørgensen SF, Reims HM, Aukrust P, Lundin KE, Fevang B.

Am J Gastroenterol. 2017 Feb;112(2):393. doi: 10.1038/ajg.2016.551. No abstract available.

PMID:
28154406
33.

Common Variable Immunodeficiency patients with a phenotypic profile of immunosenescence present with thrombocytopenia.

Stuchlý J, Kanderová V, Vlková M, Heřmanová I, Slámová L, Pelák O, Taraldsrud E, Jílek D, Králíc Ková P, Fevang B, Trková M, Hrušák O, Froňková E, Šedivá A, Litzman J, Kalina T.

Sci Rep. 2017 Jan 5;7:39710. doi: 10.1038/srep39710. Erratum in: Sci Rep. 2017 Feb 27;7:42569.

34.

Liver transplantation in patients with primary antibody deficiency.

Jørgensen SF, Macpherson ME, Bjøro K, Karlsen TH, Reims HM, Grzyb K, Fosby B, Fevang B, Aukrust P, Nordøy I.

J Allergy Clin Immunol. 2017 May;139(5):1708-1710.e2. doi: 10.1016/j.jaci.2016.10.025. Epub 2016 Dec 6. No abstract available.

PMID:
27931972
35.

Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency.

Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B.

Clin Immunol. 2017 Feb;175:69-74. doi: 10.1016/j.clim.2016.11.014. Epub 2016 Dec 3.

PMID:
27919819
36.

A potential founder variant in CARMIL2/RLTPR in three Norwegian families with warts, molluscum contagiosum, and T-cell dysfunction.

Sorte HS, Osnes LT, Fevang B, Aukrust P, Erichsen HC, Backe PH, Abrahamsen TG, Kittang OB, Øverland T, Jhangiani SN, Muzny DM, Vigeland MD, Samarakoon P, Gambin T, Akdemir ZH, Gibbs RA, Rødningen OK, Lyle R, Lupski JR, Stray-Pedersen A.

Mol Genet Genomic Med. 2016 Sep 17;4(6):604-616. eCollection 2016 Nov.

37.

Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.

Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, Erichsen HC, Forbes LR, Gu S, Yuan B, Jhangiani SN, Muzny DM, Rødningen OK, Sheng Y, Nicholas SK, Noroski LM, Seeborg FO, Davis CM, Canter DL, Mace EM, Vece TJ, Allen CE, Abhyankar HA, Boone PM, Beck CR, Wiszniewski W, Fevang B, Aukrust P, Tjønnfjord GE, Gedde-Dahl T, Hjorth-Hansen H, Dybedal I, Nordøy I, Jørgensen SF, Abrahamsen TG, Øverland T, Bechensteen AG, Skogen V, Osnes LTN, Kulseth MA, Prescott TE, Rustad CF, Heimdal KR, Belmont JW, Rider NL, Chinen J, Cao TN, Smith EA, Caldirola MS, Bezrodnik L, Lugo Reyes SO, Espinosa Rosales FJ, Guerrero-Cursaru ND, Pedroza LA, Poli CM, Franco JL, Trujillo Vargas CM, Aldave Becerra JC, Wright N, Issekutz TB, Issekutz AC, Abbott J, Caldwell JW, Bayer DK, Chan AY, Aiuti A, Cancrini C, Holmberg E, West C, Burstedt M, Karaca E, Yesil G, Artac H, Bayram Y, Atik MM, Eldomery MK, Ehlayel MS, Jolles S, Flatø B, Bertuch AA, Hanson IC, Zhang VW, Wong LJ, Hu J, Walkiewicz M, Yang Y, Eng CM, Boerwinkle E, Gibbs RA, Shearer WT, Lyle R, Orange JS, Lupski JR.

J Allergy Clin Immunol. 2017 Jan;139(1):232-245. doi: 10.1016/j.jaci.2016.05.042. Epub 2016 Jul 16. Erratum in: J Allergy Clin Immunol. 2018 Feb;141(2):832.

38.

[Atypical mycobacteria and Lady Windermere].

Falkenberg-Jensen B, Aaløkken TM, Fevang B.

Tidsskr Nor Laegeforen. 2016 Aug 23;136(14-15):1227. doi: 10.4045/tidsskr.16.0235. eCollection 2016 Aug. Norwegian. No abstract available.

39.

A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency.

Jørgensen SF, Reims HM, Frydenlund D, Holm K, Paulsen V, Michelsen AE, Jørgensen KK, Osnes LT, Bratlie J, Eide TJ, Dahl CP, Holter E, Tronstad RR, Hanevik K, Brattbakk HR, Kaveh F, Fiskerstrand T, Kran AB, Ueland T, Karlsen TH, Aukrust P, Lundin KE, Fevang B.

Am J Gastroenterol. 2016 Oct;111(10):1467-1475. doi: 10.1038/ajg.2016.329. Epub 2016 Aug 16.

PMID:
27527747
40.

Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation.

Jørgensen SF, Trøseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, Holm K, Høivik ML, Rashidi A, Dahl CP, Vesterhus M, Halvorsen B, Mollnes TE, Berge RK, Moum B, Lundin KE, Fevang B, Ueland T, Karlsen TH, Aukrust P, Hov JR.

Mucosal Immunol. 2016 Nov;9(6):1455-1465. doi: 10.1038/mi.2016.18. Epub 2016 Mar 16.

PMID:
26982597
41.

Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Elgizouli M, Lowe DM, Speckmann C, Schubert D, Hülsdünker J, Eskandarian Z, Dudek A, Schmitt-Graeff A, Wanders J, Jørgensen SF, Fevang B, Salzer U, Nieters A, Burns S, Grimbacher B.

Clin Exp Immunol. 2016 Feb;183(2):221-9. doi: 10.1111/cei.12706. Epub 2015 Nov 9.

42.

Reduction in orthopaedic surgery in patients with rheumatoid arthritis: a Norwegian register-based study.

Nystad TW, Fenstad AM, Furnes O, Havelin LI, Skredderstuen AK, Fevang BT.

Scand J Rheumatol. 2016 Jan;45(1):1-7. doi: 10.3109/03009742.2015.1050451. Epub 2015 Aug 24.

PMID:
26303149
43.

IRF4 Is a Critical Gene in Retinoic Acid-Mediated Plasma Cell Formation and Is Deregulated in Common Variable Immunodeficiency-Derived B Cells.

Indrevær RL, Moskaug JØ, Paur I, Bøhn SK, Jørgensen SF, Blomhoff R, Aukrust P, Fevang B, Blomhoff HK.

J Immunol. 2015 Sep 15;195(6):2601-11. doi: 10.4049/jimmunol.1500250. Epub 2015 Aug 14.

44.

Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells.

Li J, Jørgensen SF, Maggadottir SM, Bakay M, Warnatz K, Glessner J, Pandey R, Salzer U, Schmidt RE, Perez E, Resnick E, Goldacker S, Buchta M, Witte T, Padyukov L, Videm V, Folseraas T, Atschekzei F, Elder JT, Nair RP, Winkelmann J, Gieger C, Nöthen MM, Büning C, Brand S, Sullivan KE, Orange JS, Fevang B, Schreiber S, Lieb W, Aukrust P, Chapel H, Cunningham-Rundles C, Franke A, Karlsen TH, Grimbacher B, Hakonarson H, Hammarström L, Ellinghaus E.

Nat Commun. 2015 Apr 20;6:6804. doi: 10.1038/ncomms7804.

45.

Increased risk of revision for infection in rheumatoid arthritis patients with total hip replacements.

Schrama JC, Fenstad AM, Dale H, Havelin L, Hallan G, Overgaard S, Pedersen AB, Kärrholm J, Garellick G, Pulkkinen P, Eskelinen A, Mäkelä K, Engesæter LB, Fevang BT.

Acta Orthop. 2015;86(4):469-76. doi: 10.3109/17453674.2015.1017793. Epub 2015 Mar 17.

46.

Re: a statistical analysis of ankle prosthesis from the Norwegian Arthroplasty Register.

Lie SA, Havelin LI, Fenstad AM, Espehaug B, Dybvik E, Baste V, Engesæter LB, Skredderstuen A, Dale H, Fevang JM, Fevang BT, Hallan G, Gjertsen JE, Furnes O.

Arch Orthop Trauma Surg. 2015 Jan;135(1):17-8. doi: 10.1007/s00402-014-2120-7. Epub 2014 Nov 26. No abstract available.

PMID:
25424751
47.

Improved survival for anatomic total shoulder prostheses.

Fevang BT, Nystad TW, Skredderstuen A, Furnes ON, Havelin LI.

Acta Orthop. 2015 Feb;86(1):63-70. doi: 10.3109/17453674.2014.984113. Epub 2014 Nov 11.

48.

Hip replacement surgery in patients with ankylosing spondylitis.

Nystad TW, Furnes O, Havelin LI, Skredderstuen AK, Lie SA, Fevang BT.

Ann Rheum Dis. 2014 Jun;73(6):1194-7. doi: 10.1136/annrheumdis-2013-203963. Epub 2013 Nov 27.

PMID:
24285490
49.

Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9.

Taraldsrud E, Fevang B, Aukrust P, Beiske KH, Fløisand Y, Frøland S, Rollag H, Olweus J.

Clin Exp Immunol. 2014 Mar;175(3):439-48. doi: 10.1111/cei.12239.

50.

Retinoic acid improves defective TLR9/RP105-induced immune responses in common variable immunodeficiency-derived B cells.

Indrevær RL, Holm KL, Aukrust P, Osnes LT, Naderi EH, Fevang B, Blomhoff HK.

J Immunol. 2013 Oct 1;191(7):3624-33. doi: 10.4049/jimmunol.1300213. Epub 2013 Sep 4.

Supplemental Content

Loading ...
Support Center